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AbstrACt
Objective To create a database of long-term randomised 
controlled trials (RCTs) comparing higher with lower 
omega-3, omega-6 or total polyunsaturated fatty acid 
(PUFA), regardless of reported outcomes, and to develop 
methods to assess effects of increasing omega-6, alpha-
linolenic acid (ALA), long-chain omega-3 (LCn3) and total 
PUFA on health outcomes.
Design Systematic review search, methodology and 
meta-analyses.
Data sources Medline, Embase, CENTRAL, WHO 
International Clinical Trials Registry Platform,  Clinicaltrials. 
gov and trials in relevant systematic reviews.
Eligibility criteria RCTs of ≥24 weeks' duration assessing 
effects of increasing ALA, LCn3, omega-6 or total PUFAs, 
regardless of outcomes reported.
Data synthesis Methods included random-effects meta-
analyses and sensitivity analyses. Funnel plots were 
examined, and subgrouping assessed effects of intervention 
type, replacement, baseline diabetes risk and use of diabetic 
medications, trial duration and dose. Quality of evidence was 
assessed using Grading of Recommendations Assessment, 
Development and Evaluation (GRADE).
results Electronic searches generated 37 810 hits, de-
duplicated to 19 772 titles and abstracts. We assessed 
2155 full-text papers, conference abstracts and trials 
registry entries independently in duplicate. Included 
studies were grouped into 363 RCTs comparing higher 
with lower omega-3, omega-6 and/or total PUFA intake of 
at least 6 months’ duration—the Database. Of these 363 
included RCTs, 216 RCTs were included in at least one of 
our reviews of health outcomes, data extracted and risk of 
bias assessed in duplicate. Ninety five RCTs were included 
in the Database but not included in our current reviews. 
Of these 311 completed trials, 27 altered ALA intake, 221 
altered LCn3 intake and 16 trials altered omega-3 intake 
without specifying whether ALA or LCn3. Forty one trials 
altered omega-6 and 59 total PUFA.The remaining 52 trials 
are ongoing though 13 (25%) appear to be outstanding, or 
constitute missing data. 
Conclusions This extensive database of trials is available 
to allow assessment of further health outcomes.
bACkgrOunD
When the WHO Nutrition Guidance Expert 
Advisory Group (NUGAG) Subgroup on Diet 
and Health commissioned us to assess the 
effects of omega-3, omega-6 and total poly-
unsaturated fatty acids (PUFAs) across a wide 
range of outcomes, we realised the logical 
way to progress was not to carry out the 27 
reviews individually. Instead, we could create 
a single database of all long-term randomised 
controlled trials (RCTs) that compared 
higher with lower omega-3 or omega-6 or 
total PUFA regardless of outcomes reported. 
We could then extract all outcomes relevant 
to our reviews from this set of studies, from 
published papers, abstracts and trials registry 
entries. Even better, we could contact authors 
and ask whether they had collected any 
useful outcomes (perhaps as adverse events 
or routine clinical assessments) that they had 
not reported in publications.
Creating the database and contacting 
authors in this way would be an excellent 
way to try to reduce some aspects of publi-
cation bias (where outcomes that do not 
appear to be statistically significant are seen 
as less interesting and not published). It 
also meant that we could potentially collect 
enough data across studies to formally assess 
effects of omega-3, omega-6 and total PUFA 
on the diagnosis of common diseases, such as 
strengths and limitations of this study
 ► Extensive search for long-term trials of omega-3, 
omega-6 and total polyunsaturated fatty acid.
 ► Search date April 2017, updated in December 2018 
with rechecking of all ongoing trials.
 ► Provision of a database of all relevant randomised 
controlled trials with references to relevant papers, 
abstracts, theses and trials registry entries.
 ► Detailed methodology for the associated set of sys-
tematic reviews.
 ► We contacted many authors for further details of 
methodology and outcome data, but  we were un-
able to contact all authors due to limited resources.
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diabetes, depression and cancers, even where few studies 
formally aimed to assess these outcomes. Within the data-
base we included enough studies to develop a method 
for assessment of compliance, an important aspect of 
validity in dietary trials. Development of the database also 
provided the possibility to make the database accessible 
to others, to use as the basis of systematic reviews assessing 
additional outcomes to those requested by WHO or for 
future updates.
This paper discusses the production of the database 
of long-term RCTs assessing higher vs lower omega-3, 
omega-6 and total PUFA intake on any outcome, pres-
ents that database (in supplementary file 1; supplemen-
tary file 2; supplementary file 3) for others to use and 
provides details of the methodology used in the set of 
reviews assessing health effects. Outcomes commissioned 
by WHO, considered key in their prioritisation process, 
were cardiovascular mortality, cardiovascular events, 
coronary heart disease, atrial fibrillation, lipids, stroke, 
all-cause mortality and adiposity (all published in three 
reviews1–3), type 2 diabetes,4 depression,5 neurocogni-
tion (including dementia),6 breast cancer7 and inflam-
matory bowel disease (IBD).8 We grouped the 27 WHO 
reviews into eight papers, and all were pre-registered on 
the Cochrane Library1–3 or PROSPERO.5–9 We have also 
used the database to assess effects on musculoskeletal and 
functional outcomes in older adults (a systematic review 
not requested by WHO).10
ObjECtivEs
The primary objective of this set of systematic reviews 
was to determine health effects of higher versus lower 
omega-6, omega-3 (alpha-linolenic acid (ALA) or long-
chain omega-3 (LCn3)) or total PUFAs intake using RCTs.
Secondary objectives included creation of a dataset of 
RCTs with a duration of ≥24 weeks comparing higher 
with lower omega-3, omega-6 or total PUFA, regardless of 
reported outcomes; and assessment of effects of higher 
omega-6, ALA, LCn3 and total PUFA on mortality; cardio-
vascular diseases (CVDs); IBD; cancers; glucose metab-
olism and diabetes; neurological outcomes, including 
cognition, depression and anxiety; musculoskeletal and 
functional outcomes; measures of body fatness; and 
serum lipids over appropriate durations.
MEthODs
Criteria for considering studies for this review
We carried out this set of reviews in two stages. First, we 
created a database of all ongoing and completed RCTs of 
higher versus lower omega-6, ALA, LCn3 and total PUFA 
with a duration of ≥24 weeks. From this database of rele-
vant studies, we selected RCTs for individual reviews.
Six months was chosen as the minimum duration after 
considering equilibration of PUFAs into body tissues. 
Careful work by Browning et al11 suggests LCn3 supple-
ments equivalent to one portion/week of oily fish reach 
95% of maximal incorporation by 5 days for eicosapen-
taenoic acid (EPA) in plasma phosphatidylcholine 
(95% CI 0 to 18 days) but by 273 days for docosahexae-
noic acid (DHA) into blood mononuclear cells (95% CI 
0 to 670 days). While this suggests individual variability, 
on average, all compartments except blood mononuclear 
cells had equilibrated by 117 days. The authors stated 'EPA 
and DHA reached a maximum in platelets in 3–4 weeks 
and 1–2 months, respectively, and in blood mononuclear 
cells in 6–9 months’. We chose 6 months (24 weeks) as 
the minimum duration of intervention to allow equilibra-
tion of most body compartments. For specific reviews with 
outcomes needing additional months for body composi-
tion changes to affect health, we set the minimum trial 
duration at 1 year.
inclusion criteria for the rCt database
We included RCTs with a duration of ≥24 weeks (≥168 
days) of continuous involvement and comparing higher 
with lower omega-6, omega-3 (ALA or LCn3) and/or total 
PUFA intakes. We included studies reported as full text, 
abstracts only, trials registry entries and/or unpublished 
data. We included cluster-randomised studies with ≥6 
clusters. Participants were adults (≥18 years old), but we 
excluded studies of participants who were pregnant or 
acutely ill (with diagnosed current cancer, undergoing 
heart or renal transplantation, with HIV or AIDS, on 
haemodialysis, with IgA glomerulonephritis or any other 
renal problem except in diabetes). Our reasoning was to 
exclude people with conditions that may affect the rela-
tionship between polyunsaturated fats and cardiovascular 
events. Studies were included in the database regardless 
of reported outcomes.
Interventions could include dietary supplementation, 
a provided diet and/or advice on diet. Supplementation 
had to be in oil or capsule form, or as foodstuffs provided, 
to be consumed by mouth (we excluded enteral/paren-
teral feeds and enemas). Studies were included if they 
compared the effect of this intervention with usual diet; 
no advice; no supplementation or placebo (as appro-
priate); or with lower omega-3, omega-6 and/or total 
PUFA intake, so long as they created higher versus lower 
omega-3, omega-6 or total PUFA arms. We also included 
trials directly comparing omega-3 with omega-6.
Omega-3 trials could aim to increase LCn3 and/
or ALA. LCn3 includes EPA, DHA and docosapentae-
noic acid in oily fish, fish, concentrated or algal oils. 
ALA includes refined ALA or products such as oils with 
an ALA content of ≥10% of the total fat content, such 
as linseed (flax), canola (rapeseed), perilla, purslane, 
mustard seed, candlenut, stillingia or walnut as a food or 
oil, made into a spreading fat or supplementing another 
food. Sources and types of omega-3 and omega-6 fatty 
acids are discussed and defined in supplementary text 1 
(supplementary file 4). Omega-6 included linoleic acid 
(LA), gamma-linoleic acid (GLA), arachidonic acid (AA) 
or any combination, as a supplement or dietary compo-
nent high in omega-6, such as sunflower oil. Omega-6 
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advice, foodstuffs or supplements had to aim to increase 
or decrease omega-6 intake or, if no clear aim was stated 
(but implied, such as aiming to provide a 'heart health' or 
a 'Mediterranean' diet), the intervention had to achieve 
an increase or a decrease of ≥10% of baseline omega-6. 
We included trials as increasing total PUFA intake where 
they stated an aim to increase total PUFA or a dietary 
component high in total PUFA intake, such as vegetable 
oil, or where the intervention led to an increase or a 
decrease of ≥10% of baseline total PUFA.
Studies with multiple risk factor intervention on life-
style factors, such as weight, smoking, physical activity, 
or dietary interventions not involving dietary fats, were 
not included, except where the other intervention was a 
direct replacement for polyunsaturated fats or the effect 
of diet or supplementation could be separated from other 
interventions.
search methods for identification of studies
We ran two sets of searches on CENTRAL (Cochrane), 
MEDLINE and EMBASE to 27 April 2017, and on  Clini-
calTrials. com and the WHO International Clinical Trials 
Registry Platform to September 2016. We also checked 
included trials of relevant systematic reviews and wrote 
to authors of included studies for additional studies and 
trial data (including unpublished outcome data). The 
first search strategy for MEDLINE (Ovid) was adapted 
from Al-Khudairy et al12 and was also used to locate trials 
of polyunsaturated fats (see supplementary text 2 in 
supplementary file 4). The second set of search strate-
gies aimed to locate omega-3 trials and was adapted from 
Hooper et al13 (see supplementary text 3, supplementary 
file 4). These complex strategies were adapted for use in 
the other databases. The Cochrane sensitivity and preci-
sion-maximising RCT filter was applied to MEDLINE 
(Ovid) and for EMBASE, and terms recommended in 
the Cochrane Handbook for Systematic Reviews of Interven-
tions were applied.14 To ensure the database is up to date, 
we re-searched all ongoing trials in December 2018 and 
included four previously ongoing trials,15–18 adding data 
on a further 50 239 participants in trials from 1.0 to 7.4 
years to dataset 1 (supplementary File 1).
Titles and abstracts located by these searches were down-
loaded, de-duplicated into EndNote software, assessed 
as a single set for inclusion in the database and used as 
the wider study pool from which included studies for 
individual reviews were selected. Included studies in all 
identified relevant systematic reviews were checked, and 
additional publications of included trials were obtained. 
Attempts were made to obtain full-text translations and/
or evaluations of all relevant non-English articles.
Assessment of inclusion
Review methods were based on those of the Cochrane 
Collaboration.19 Two review authors independently 
screened titles and abstracts for inclusion into the wider 
database (using EndNote software) and coded them as 
'retrieve' (eligible or potentially eligible/unclear) or 
'do not retrieve'. All those coded for retrieval by either 
reviewer were collected in full text, and two review 
authors independently screened the full text, assessed 
studies for inclusion, and identified and recorded reasons 
for exclusion of ineligible studies (LH and one other 
reviewer) using an inclusion/exclusion form. We resolved 
disagreements through discussion or consulted a third 
reviewer (AA). We identified and excluded duplicates 
and collated multiple publications and abstracts for each 
trial (as studies rather than publications were the unit of 
interest). We recorded selection to allow completion of 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses flow diagram. The database was compiled 
within RevMan software20 in the format of Cochrane 
Characteristics of Included Studies tables (so additional 
training was not needed) and transcribed into Word, with 
references added in EndNote to create the Database.
inclusion criteria for specific reviews
Database studies were assessed for inclusion into specific 
reviews. Trials of ≥12 months’ duration were included 
in CVD, mortality and cancer reviews,1–3 7 where they 
assessed any of the review’s primary or secondary 
outcomes (table 1). Trials of ≥6 months were included 
into the glucose metabolism and diabetes, depression 
and anxiety, IBD and inflammatory markers, and neuro-
cognitive and functional outcomes reviews,4 6 8 21 22 where 
they assessed any of the review’s primary or secondary 
outcomes (table 2). For each study included in a review, 
all primary, secondary and tertiary outcomes were data 
extracted.
Data collection and analysis for trials included in at least one 
systematic review
A data extraction form was designed for this set of reviews 
and tested by each reviewer on a common ‘training’ study. 
Two review authors each extracted study characteristics 
independently in duplicate onto a Word data extraction 
form (by hand or electronically). Characteristics included 
bibliographical details, methods (study design, total 
duration of study, details of any 'run-in' period, number 
of study centres and location, study setting, withdrawals 
and date of study), details of participants, interventions, 
comparators and outcomes, process data (dietary intake 
or body fat data), trial funding, risk of bias assessments, 
trial registration data, effect modifiers and adverse events. 
Dichotomous data from dietary advice studies were 
extracted at the latest point available in the trial (regard-
less of the amount of reinforcement of the original dietary 
message), while dichotomous data from supplemental 
studies were extracted to the point that supplementation 
ended, or the trial ended, whichever was earlier. Contin-
uous data were extracted at the latest point available in 
fixed-term trials, but in studies where participants were 
followed up for varying durations, participants' data were 
extracted from the first time point following the mean 
trial duration. Data from periods following the end of a 
trial were not used in the meta-analysis. Where papers 
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reported continuous results as change from baseline, we 
used these data; otherwise, we used data at the latest point 
available (so long as the change in either arm from base-
line was greater than the difference between arms at base-
line, to exclude trials with very unbalanced baselines). We 
did not impute change data.
Disagreements were resolved by discussion and/or a 
third reviewer (LH or AA). For dichotomous outcomes, 
we extracted the number of participants in whom an 
outcome was assessed and the number of participants 
experiencing the outcome for each study arm. For contin-
uous outcomes, the number of participants assessed, 
the mean and the variance in each arm were extracted 
(SDs were calculated from other variance data using the 
RevMan calculator).
Risk of bias was assessed using the Cochrane Risk of 
Bias tool23 and two additional domains, independently 
in duplicate alongside data extraction. We assessed atten-
tion bias and compliance as we felt these are important in 
dietary trials:
1. Random sequence generation (selection bias).
2. Allocation concealment (selection bias).
3. Blinding of participants and personnel (performance 
bias).
4. Blinding of outcome assessment (detection bias).
5. Incomplete outcome data (attrition bias).
6. Selective outcome reporting (reporting bias).
7. Attention bias (an aspect of performance bias, inter-
vention participants receive more time and/or atten-
tion from study and/or health personnel during the 
trial).
8. Compliance (we considered studies to be at low risk of 
compliance bias when compliance was assessed, results 
of compliance assessment were clearly reported for all 
arms and where most participants appeared to have 
taken ≥75% of the intended fatty acid dose).
Further details about assessment of each domain 
are found in supplementary table 1 (supplementary file 
4). Compliance data are difficult to interpret and assess 
in dietary trials, as compliance can be assessed in many 
ways. These include counting return of unused supple-
ments or foods, participant collection of foods or supple-
ments, intake self-report (including diaries) and/or 
changes in body measures of fatty acids (eg, fatty acids 
in plasma cholesteryl esters). For these reviews, we devel-
oped an assessment method for compliance that incor-
porated all these possible assessment methods (detailed 
in supplementary figure, supplementary file 4). For one 
review, where trial inclusion relied heavily on compliance 
evidence, we were stricter, insisting on evidence of differ-
ences in body markers of total PUFA or of total serum 
cholesterol, between intervention and control arms.2
We graded each potential source as high, low or unclear 
risk of bias and provided details from the study reports, 
Table 1 Primary, secondary and tertiary outcomes for the systematic reviews assessing effects of omega-3, omega-6 and 
total polyunsaturated fatty acid on cardiovascular outcomes, cancers and mortality, including only trials of ≥12 months duration
Review
Primary and secondary outcomes—
studies were included whenever these 
outcomes were assessed by trialists 
(even if not fully or appropriately 
reported). All these outcomes were data 
extracted and analysed when data were 
found.
Tertiary outcomes— where a study was 
included, these outcomes were also data 
extracted and analysed.
CVD and mortality1–3  ► Cardiovascular mortality.
 ► Cardiovascular events.
 ► Coronary heart disease events.
 ► Lipids.
 ► Stroke.
 ► All-cause mortality.
 ► Adiposity.
 ► Atrial fibrillation.
 ► Myocardial infarction. 
 ► Sudden cardiac death.
 ► Peripheral vascular events.
 ► Heart failure.
 ► Revascularisation.
 ► Angina.
 ► Blood pressure.
 ► QoL.
 ► Economic costs.
 ► Serious adverse events.
Cancer7  ► Cancer diagnosis, recurrence and 
mortality.
 ► Breast cancer diagnosis and mortality.
 ► Markers of risk, such as prostate-
specific antigen for prostate cancer and 
breast density for breast cancer.
 ► QoL.
 ► Body weight.
 ► Adiposity measures.
 ► Dropouts.
CVD, cardiovascular disease; QoL, quality of life.
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Table 2 Primary, secondary and tertiary outcomes for the systematic reviews assessing effects of omega-3, omega-6 and 
total polyunsaturated fatty acid on key health outcomes, including trials of ≥6 months' duration
Review
Primary and secondary outcomes—
studies were included whenever these 
outcomes were assessed by trialists 
(even if not fully or appropriately 
reported). All these outcomes were 
data extracted and analysed when data 
were found.
Tertiary outcomes—where a study was included, 
these outcomes were also data extracted and 
analysed.
Depression and anxiety21  ► Depression
 – Incidence.
 – Continuous measures.
 – 50% reduction (remission).
 ► Anxiety
 – Incidence.
 – Continuous measures.
 – 50% reduction (remission).
 ► Social participation.
 ► QoL.
 ► Carer stress.
 ► Healthcare and patient costs.
 ► Adherence.
 ► Fidelity.
 ► Adverse events.
 ► Withdrawal rates.
 ► Withdrawals due to non-compliance, lack of efficacy 
and/or side effects.
 ► Psychosis, suicidality, suicide and self-harm.
IBD and inflammatory markers8  ► Remission.
 ► Relapse.
 ► Severity scores.
 ► Diagnosis of inflammatory bowel 
disease  (new cases).
 ► Inflammatory markers, including 
C reactive protein, interleukin 6, 
erythrocyte sedimentation rate and 
faecal calprotectin.
 ► Corticosteroid, immunosuppressant, 
immunomodulatory use.
 ► QoL.
 ► Adiposity.
 ► Other inflammatory markers, such as TNFalpha, 
ICAM-1 VCAM-1.
Neurocognitive outcomes6  ► Change in cognitive function or 
score, such as Mini-Mental State 
Examination (MMSE), Alzheimer's 
Disease Assessment Scale Cognitive 
Subscale (ADAS-Cog) and Clinical 
Dementia Rating (CDR).
 ► Change in memory.
 ► New diagnosis of dementia or 
cognitive impairment.
 ► QoL.
 ► ADLs for example, Barthel score.
 ► Adherence or compliance.
 ► Safety.
 ► Tolerability.
 ► Economic costs.
 ► Mortality.
Diabetes4  ► New diagnosis of diabetes.
 ► Prediabetes diagnosis, for example, 
impaired fasting glucose (IFG), 
impaired glucose tolerance (IGT) and 
impaired glucose regulation (IGR).
 ► Changes in glucose, for example, 
fasting or postprandial glucose or 
glycated haemoglobin (HbA1c).
 ► Change in insulin or insulin resistance.
 ► Homeostatic Model Assessment of 
Insulin Resistance (HOMA-IR).
 ► Progression of diabetes, for example, 
change in treatment strategy, newly 
diagnosed retinopathy, neuropathy or 
nephropathy.
 ► Change in serum triglycerides.
 ► Change in serum total cholesterol.
 ► Change in body mass index or other measures of 
adiposity.
 ► All-cause mortality.
 ► Diabetic mortality.
Musculoskeletal and functional ability22  ► Fracture incidence.
 ► Bone mineral density or bone mass.
 ► Bone turnover markers.
 ► Sarcopenia or dynapenia incidence.
 ► Skeletal muscle mass.
 ► Measures of functional status, for 
example, Barthel Index, ADLs, 
mobility scores.
 ► Strength or physical performance.
ADL, activity of daily living; QoL, quality of life. 
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unpublished data and/or author correspondence to 
justify the judgement. We used this to assess summary risk 
of bias for each trial.
summary risk of bias
Supplement or capsule-type trials were considered to be 
at low summary risk of bias where randomisation, alloca-
tion concealment, blinding of participants, and personnel 
and blinding of outcome assessors were all judged low 
risk. All other trials were considered at moderate or high 
risk of bias. A dietary advice or all-food provided-type trial 
was judged at low summary risk of bias where randomis-
ation, allocation concealment and blinding of outcome 
assessors were all judged adequate (all others were at 
moderate or high risk). We originally planned to assess 
summary risk of bias in the same way for all trials, but the 
WHO NUGAG expert group requested we assess summary 
risk of bias slightly differently in different types of trials. 
Research suggests that poorly concealed allocation is 
associated with 40% greater effect size, so randomisation 
and allocation concealment are core items for risk of bias 
assessment.24 Lack of blinding is associated with smaller 
levels of bias,25 especially where outcomes are objectively 
measured,26 as were most of those in our reviews, but 
small amounts of bias can be important where effect sizes 
are small.
Measures of treatment effect
Dichotomous data were analysed as risk ratios (RRs) 
with 95% CIs and continuous data as mean difference 
(MD) with 95% CIs. Where studies assessed effects using 
different but comparable scales, we standardised scales so 
that they presented with a consistent direction of effect 
(multiplying by −1 as needed) then combined using stan-
dardised MDs. Skewed data reported as medians were 
discussed, and medians were added to relevant forest plots 
to allow visual comparison of findings (but not pooled).
Where included studies had more than two interven-
tion arms and separate control arms for each intervention 
arm, the relevant control arm was used for each inter-
vention arm. Where there was a single control group, we 
combined intervention arms to compare with the single 
control group or used the single most relevant interven-
tion group (to prevent participants appearing more than 
once in any meta-analysis). In factorial trials where only 
one intervention was relevant to our reviews, we used the 
relevant factorial analysis, but where we were interested in 
several interventions (cf AlphaOmega and Diet and Rein-
farction Trial),27 28 we ensured the two interventions were 
never combined in the meta-analysis.
To minimise missing data, we attempted to contact 
authors of included and ongoing RCTs (including those 
identified only via trials registry entries or conference 
abstracts), to request data on review outcomes and key 
methods information. An RCT was included in a review 
where data on at least one review outcome had been 
measured (and for dichotomous outcomes, at least one 
person had experienced the outcome). Due to funding 
constraints, we were not able to contact all study authors.
Data synthesis
We conducted meta-analyses only when participants, 
comparisons and outcomes were similar enough to 
address a sensible question. Primary analyses assessed 
effects of LCn3, ALA, omega-6 and total PUFA on primary 
outcomes. Meta-analyses were carried out in RevMan 
2014.20 Differences between lower and higher PUFA intake 
arms were combined across studies using RR or MDs in 
random-effects meta-analysis. We used a random-effects 
model because dietary interventions are more complex 
and heterogeneous than many medical treatments, but 
we used fixed-effects meta-analysis in sensitivity analyses 
(to check that our results were robust to differing assump-
tions). We also carried out sensitivity analyses to assess 
effects of methodological rigour, retaining only studies at 
low summary risk of bias, studies at low risk of compliance 
bias and larger trials (randomising ≥100 participants).
We used I² to measure heterogeneity between trials in 
each analysis.29 Substantial heterogeneity (I²>50%) was 
reported, and we explored possible causes using prespec-
ified subgroup analyses. We intended to assess reporting 
biases using a funnel plot only for forest plots with ≥10 
trials; however, we sometimes ran funnel plots on key 
outcomes with only eight or nine trials (never <8), to 
assess possible biases.
subgrouping
We explored potential heterogeneity in the effects of 
omega-6, ALA, LCn3 or total PUFA on primary outcomes 
by performing prespecified subgroup analyses for all 
reviews:
1. Intervention type (dietary advice, supplementary cap-
sules, supplemental foods or all foods provided).
2. Dose of LCn3, ALA, omega-6 and total PUFA (and 
dose response), where dose was the difference in dose 
between two arms:
a. LCn3 intake: ≤150 mg/d, >150 to ≤250 mg/d, 
>250 to ≤400 mg/d, >0.4 to ≤2.4 g/d, >2.5 to ≤4.4 g/d, 
>4.4 g/d.
b. ALA intake: <5 g/d, ≥5 g/d.
c. omega-6 intake: ≤4%E, >4%E. 
d. total PUFA: <1%E, one to <2%E, two to <5%E, 
≥5%E.
3. Trial duration: 6 to <12 months where included, 12 
to <24, 24 to <48 and ≥48 months.
4. Replacement of saturated fatty acids (SFA), mono-
unsaturated fatty acids (MUFA), carbohydrate, other 
PUFA, nil and unclear.
5. Baseline risk of outcome (categories varied by out-
come type).
6. Medication use (≥50% of control group on relevant 
medication vs <50% on such medication—statins 
for CVD outcomes, antidiabetics for diabetes out-
comes and antidepressants for depression outcomes).
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7. Baseline LCn3, ALA, omega-6 or total PUFA intake (as 
appropriate).
8. Change in the omega-3/omega-6 ratio.
Some reviews included additional subgroups, including 
participants' sex, participants' age and omega-6 type (LA 
or GLA). The test for subgroup interactions in Review 
Manager V.5 was used.20
interpretation
Outcome data were interpreted as follows:
1. Is there an effect on this outcome? (options: ‘increased 
risk’, ‘decreased risk’ or ‘little or no effect’). For di-
chotomous data, RR <0.92 or >1.08 for the highest 
quality evidence (main analysis and sensitivity analy-
ses) suggested increased or decreased risk (otherwise 
little or no effect). Presence or absence of an effect was 
not decided by statistical significance.
2. For continuous outcomes, the effect threshold was a 
change of ≥5% from baseline, except for measures 
where effects are clearly cumulative (such as body 
weight) when ≥2% change from baseline was consid-
ered a relevant effect size.
3. Quality of evidence was assessed using GRADE assess-
ment30 (Grading of Recommendations Assessment, 
Development and Evaluation) for key outcomes, and 
displayed in summary of findings tables. We used the 
five GRADE considerations (risk of bias, consistency of 
effect, imprecision, indirectness and publication bias) 
to assess quality of evidence as it related to the studies 
that contributed to the meta-analyses using GRADEpro 
GDT software.31 We justified decisions on downgrad-
ing using footnotes.
4. Quality judgements were interpreted (as suggested by 
Cochrane) into clear statements about the evidence 
base (high-quality evidence suggests effect/lack of ef-
fect, and moderate-quality evidence suggests a prob-
able effect; for low-quality evidence, there may be an 
effect, and for very low-quality evidence, any effects are 
unclear as the evidence is of very low quality).
5. Where there was a suggested effect, the effect size was 
described using number needed to treat (NNT) or ab-
solute risk reduction (ARR).
Using this method, some small statistically significant 
findings were considered to have ‘little or no effect’, and 
larger non-statistically significant findings could suggest 
increased or decreased risk.
Patient and public involvement
We did not involve patients or the public in this research 
at any stage.
rEsults
The electronic searches generated 37 810 hits, de-du-
plicated to 19 772 titles and abstracts. We assessed these 
plus 88 studies included in related systematic reviews (53 
studies included in two previous reviews,12 13 35 references 
found in 226 related systematic reviews but not picked 
up by our searches) and 986 potentially relevant trials 
registry entries (519 from  ClinicalTrials. gov and 467 from 
WHO International Clinical Trials Registry Platform). A 
total of 2155 full-text papers, conference abstracts and 
trials registry entries were collected and independently 
assessed for inclusion by two reviewers. Included studies 
were grouped into 363 RCTs comparing higher with lower 
omega-3, omega-6 and/or total PUFA intake of at least 
6 months duration—the trials database (see figure 1 for 
the flow diagram). Additional publications of these RCTs 
were searched (85 further items located), and authors 
were contacted where possible.
These 363 trials constitute the database of omega-3, 
omega-6 and total PUFA RCTs with a duration of at least 
6 months. Of these 363 included RCTs, 216 RCTs (dataset 
1, supplementary file 1) were included in at least one 
of our reviews of health outcomes, and consisted of 720 
papers, abstracts and theses, 96 trial registrations and 
91 sets of author correspondence.1–4 6–8 21 22 The dataset 
includes references to all the paperwork we were able to 
locate on each trial, to support complete data extraction 
on methods, baseline characteristics and outcomes. 
These 216 trials were data extracted and risk of bias 
was assessed in duplicate, and their characteristics, risk 
of bias assessments, trials registry details and references 
are detailed in dataset 1 (supplementary file 1). The trials 
include 183 791 randomised participants, and 18 trials 
randomised at least 1000 participants. Seven were hard-
er-to-find trials only published in the form of conference 
abstracts, and one was not published in English. Details of 
which trials were included in which reviews are found in 
supplementary table 2 (supplementary file 4).
Ninety-five RCTs were included in the database but 
were not included in any of our current reviews (dataset 
2, supplementary file 2), so these were not data extracted 
or risk of bias assessed in duplicate (including 146 papers 
and abstracts, 8 trial registrations and 25 sets of author 
correspondence). Brief characteristics, trials registry 
details and references of these 95 trials have been detailed 
in dataset 2  (Supplementary file 2).
Of these 311 completed trials (within datasets 1 and 2):
 ► Twenty-seven trials altered ALA intake.
 ► Two hundred twenty-one trials altered LCn3 intake.
 ► Sixteen trials altered omega-3 intake without speci-
fying whether ALA or LCn3.
 ► Forty-one trials altered omega-6 fats.
 ► Fifty-nine trials altered total PUFA (see details trial by 
trial in supplementary table 3 (supplementary file 4)).
Several trials had interventions that fitted more than 
one of these groupings, so the numbers do not add to 
311. Of these 116 sets of author correspondence, most 
provided data on at least one additional outcome, and 
most provided methodological data.
For the remaining 52 trials, we found protocols, baseline 
data reports and/or trial registrations but no published 
outcomes, so we classified them as ongoing (including 
28 papers or abstracts, 55 trial registrations and 5 sets 
of author correspondence). Brief characteristics, trials 
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registry details and any references are detailed in Dataset 
3 (supplementary file 3). Of these 52 RCTs, 5 were 
expected to be completed before 2012, and 8 had unclear 
completion dates but would have been expected to be 
published by 2015, given intervention duration and start 
dates, so 13 (25%) appear to be outstanding or may 
constitute missing data.
Characteristics of the included trials and their risk of 
bias have been summarised review by review to enable 
readers to make sense of review findings. The tables of 
characteristics of included studies, along with references 
to the full set of relevant publications, and data on risk of 
bias constitute the database, including datasets 1, 2 and 3. 
If researchers would like access to information provided 
by trialists, they are welcome to request it from the first 
author.
Risk of bias was formally assessed in duplicate for the 
216 RCTs included in our set of systematic reviews. Of 
these, 42 (19%) were found to be at low summary risk of 
bias (at low risk from selection and detection bias and at 
low risk of performance bias where trials provided supple-
ments; figure 2 and supplementary file 1).
DisCussiOn
We have carefully compiled this database of longer term 
trials of omega-3, omega-6 and total PUFA interventions, 
including completed and ongoing trials. This large set of 
trials has been partially characterised and assessed for risk 
of bias, and the full database is presented here as a back-
ground to our reviews, but also to allow others to use this 
database to conduct further systematic reviews more quickly 
and efficiently (without the need for extensive searching for 
these trials). We have aimed, where possible, to contact trial 
authors and to collect data on outcomes of interest to us but 
were not reported in formal publications. This has allowed 
us to access data not previously made available and has 
allowed some analyses (such as assessing effects of omega-3 
fats on diabetes and depression diagnoses4 21) that were not 
previously informative.
Because high-quality systematic review methodology is 
important in understanding research evidence, we have 
aimed to be explicit in how we made decisions within this 
review. This allows discussion and disagreement and, we 
hope, will ultimately lead to improvements in methodology 
of nutritional systematic reviews. Some aspects of assess-
ment of risk of bias within our reviews are worthy of note 
as they engendered a great deal of discussion between team 
members. When assessing blinding of participants and 
personnel (when assessing performance bias), we did not 
require that smell and taste were masked to achieve low-risk 
status, just that attempts had been made to create a visually 
equivalent placebo. As fish oil capsules can provide a fishy 
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for the set of 
reviews. PUFA, polyunsaturated fatty acid; RCT, randomised controlled trial.
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after-taste, this may be a mistake, and some trials did care-
fully add citrus or mint flavours to intervention and control 
capsules, while others added a small amount of fish oil to 
control capsules to support masking. Almost no trials reported 
results of assessments to assess the success of masking, which 
would have been useful to support assessments.
When we established contact with trial authors and asked 
them questions about the methodology of their trial, we 
sometimes found that an author would say ‘yes, allocation was 
concealed’ or ‘participants were not aware of whether they 
were taking the intervention or control’ without providing 
requested information on methods to achieve them. We 
decided to take the author’s word for the results of their 
methods in these cases, even where methodological justifi-
cation was not provided. Finally, when checking whether all 
primary and secondary outcomes mentioned in the study 
protocol or trials register were also reported in study publi-
cations, we accepted studies as being at low summary risk 
of reporting bias when they reported additional outcomes 
(not mentioned earlier) in study reports (after some debate 
within our team). These boundaries were all much argued. 
We made allowances as these issues take trials to the limits 
of usual methodological reporting standards. However, we 
suggest that some of these issues may undermine trial meth-
odological strength, even where trials were assessed by us as 
at low summary risk of bias.
We developed a system to assess risk of bias associated with 
compliance—compliance assessment is complicated in this 
database (and in many nutritional studies) as compliance 
could be reported in terms of returned capsules, self-re-
ported intake (including diaries, recall and food frequency 
questionnaires), serum lipids and/or a variety of body 
composition measures. We developed a system to merge a 
variety of commonly reported measures (supplementary 
figure, supplementary file 4) and did not require plasma/
serum readings to accept compliance, except in the single 
review where compliance was used as an inclusion criteria.2 
Assessment of compliance using different methods within a 
single trial was not always in agreement, so clearly, further 
research is needed on how best to assess compliance when 
including dietary trials in systematic reviews. We hope that 
our system will provide a starting point for further method-
ological work.
We developed and used the concept of a study at low 
summary risk of bias (a study at low risk from selection and 
performance bias, and also at low risk from performance 
bias where supplements were provided). We ran sensitivity 
analyses limiting to trials at low summary risk of bias. Where 
we had substantial numbers of trials (assessing cardiovas-
cular effects of LCn3), we found that studies at low summary 
risk of bias appeared to suggest effect sizes closer to null than 
studies at moderate or high risk of bias.1 This suggests that 
this method of assessing summary risk of bias may have some 
utility.
This database has been used as the basis for our set of 
systematic reviews assessing health effects of omega-3, 
omega-6 and total polyunsaturated fats1–4 6–8 21 22 and is avail-
able as a resource for others.
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